Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 325

1.

Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment.

Macchia G, Deodato F, Cilla S, Legge F, Carone V, Chiantera V, Valentini V, Morganti AG, Ferrandina G.

Oncol Lett. 2016 May;11(5):3446-3450. Epub 2016 Mar 29.

2.

Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.

Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G.

Eur J Cancer. 2016 May;59:22-33. doi: 10.1016/j.ejca.2016.01.017. Epub 2016 Mar 19.

PMID:
26998845
3.

Laparoscopic Versus Laparotomic Surgical Staging for Early-Stage Ovarian Cancer: A Case-Control Study.

Gallotta V, Petrillo M, Conte C, Vizzielli G, Fagotti A, Ferrandina G, Fanfani F, Costantini B, Carbone V, Scambia G.

J Minim Invasive Gynecol. 2016 Mar 16. pii: S1553-4650(16)00140-0. doi: 10.1016/j.jmig.2016.03.006. [Epub ahead of print]

PMID:
26995493
4.

Laparoscopic Management of Ovarian Cancer Patients With Localized Carcinomatosis and Lymph Node Metastases: Results of a Retrospective Multi-institutional Series.

Gallotta V, Ghezzi F, Vizza E, Fagotti A, Ceccaroni M, Fanfani F, Chiantera V, Ercoli A, Rossitto C, Conte C, Uccella S, Corrado G, Scambia G, Ferrandina G.

J Minim Invasive Gynecol. 2016 May-Jun;23(4):590-6. doi: 10.1016/j.jmig.2016.01.029. Epub 2016 Feb 10.

PMID:
26872630
5.

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.

Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G.

Ann Oncol. 2016 Mar;27(3):487-93. doi: 10.1093/annonc/mdv608. Epub 2015 Dec 17.

PMID:
26681678
6.

miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.

Sestito R, Cianfrocca R, Rosanò L, Tocci P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A, Blandino G, Bagnato A.

Oncotarget. 2016 Jan 26;7(4):4009-23. doi: 10.18632/oncotarget.6546.

7.

Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma.

Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Veglione M, Castro VD, Spadaro F, Ferrandina G, Bagnato A, Rosanò L.

Oncogene. 2015 Nov 2. doi: 10.1038/onc.2015.403. [Epub ahead of print]

PMID:
26522724
8.

Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical cancer: a dose-escalation study.

Macchia G, Cilla S, Deodato F, Legge F, Di Stefano A, Chiantera V, Scambia G, Valentini V, Morganti AG, Ferrandina G.

Br J Radiol. 2015;88(1055):20150385. doi: 10.1259/bjr.20150385. Epub 2015 Sep 21.

PMID:
26388108
9.

Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer.

Petrillo M, Zannoni GF, Martinelli E, Pedone Anchora L, Ferrandina G, Tropeano G, Fagotti A, Scambia G.

PLoS One. 2015 Sep 3;10(9):e0136654. doi: 10.1371/journal.pone.0136654. eCollection 2015.

10.

Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.

Villa P, Lassandro AP, Amar ID, Vacca L, Moruzzi MC, Ferrandina G, Terribile D, Masetti R, Scambia G.

Menopause. 2016 Jan;23(1):33-9. doi: 10.1097/GME.0000000000000515.

PMID:
26308233
11.

Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review.

Minucci A, Scambia G, Santonocito C, Concolino P, Canu G, Mignone F, Saggese I, Guarino D, Costella A, Molinario R, De Bonis M, Ferrandina G, Petrillo M, Scaglione GL, Capoluongo E.

Expert Rev Mol Diagn. 2015;15(10):1383-403. doi: 10.1586/14737159.2015.1081059. Epub 2015 Aug 26.

PMID:
26306726
12.

In Reply to Govardhan et al.

Ferrandina G.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):213-4. doi: 10.1016/j.ijrobp.2015.04.008. No abstract available.

PMID:
26279040
13.

On the cutting edge of intensity modulated radiotherapy and simultaneous integrated boost (IMRT-SIB): The case of a patient with 8 brain metastases.

Ferro M, Cilla S, Macchia G, Deodato F, Pierro A, Digesu' C, Ferrandina G, Ciuffreda M, Sallustio G, Morganti AG.

Rep Pract Oncol Radiother. 2015 Jul-Aug;20(4):316-9. doi: 10.1016/j.rpor.2014.09.001. Epub 2014 Sep 23.

PMID:
26109921
14.

Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies.

Legge F, Chiantera V, Macchia G, Fagotti A, Fanfani F, Ercoli A, Gallotta V, Morganti AG, Valentini V, Scambia G, Ferrandina G.

Gynecol Oncol. 2015 Jul;138(1):83-8. doi: 10.1016/j.ygyno.2015.04.035. Epub 2015 May 1.

PMID:
25940427
15.

Laparoscopic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study.

Gallotta V, Ferrandina G, Chiantera V, Fagotti A, Fanfani F, Ercoli A, Legge F, Costantini B, Gueli Alletti S, Bottoni C, Anchora LP, Nero C, Scambia G.

J Minim Invasive Gynecol. 2015 Jul-Aug;22(5):877-83. doi: 10.1016/j.jmig.2015.04.014. Epub 2015 Apr 28.

PMID:
25929741
16.

Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study.

Ferrandina G, Gambacorta A, Gallotta V, Smaniotto D, Fagotti A, Tagliaferri L, Foti E, Fanfani F, Autorino R, Scambia G, Valentini V.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):778-85. doi: 10.1016/j.ijrobp.2014.07.033. Epub 2014 Oct 18.

PMID:
25585781
17.

Management of bilateral malignant ovarian germ cell tumors: a MITO-9 retrospective study.

Sigismondi C, Scollo P, Ferrandina G, Candiani M, Angioli R, Viganò R, Scarfone G, Mangili G.

Int J Gynecol Cancer. 2015 Feb;25(2):203-7. doi: 10.1097/IGC.0000000000000358.

PMID:
25569816
18.

Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?

Ottolina J, Ferrandina G, Gadducci A, Scollo P, Lorusso D, Giorda G, Breda E, Savarese A, Candiani M, Zullo F, Mangili G.

Gynecol Oncol. 2015 Feb;136(2):230-4. doi: 10.1016/j.ygyno.2014.12.016. Epub 2014 Dec 17.

PMID:
25527364
19.

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.

Ferrandina G, Corrado G, Mascilini F, Malaguti P, Samaritani R, Distefano M, Masciullo V, Di Legge A, Savarese A, Scambia G.

BMC Cancer. 2014 Dec 13;14:947. doi: 10.1186/1471-2407-14-947.

20.

Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy.

Bosetti R, Ferrandina G, Marneffe W, Scambia G, Vereeck L.

Nanomedicine (Lond). 2014 Jul;9(14):2175-86. doi: 10.2217/nnm.14.150.

PMID:
25405795
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk